Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Rosiglitazone
Glyburide
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring insulin resistance, type 2 diabetes, myocardial perfusion, nitrosative stress, thiazolidinediones
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes
- 30-75 years of age
- less than 1% fluctuation in HbA1c over 3 months
- women must be on contraception
- HbA1c 6-9%
- willingness to sign approved consent form
Exclusion Criteria:
- Nursing mothers, pregnant women (excluded by a negative pregnancy test).
- Subjects requiring insulin therapy (>20 units/day) and can not be converted to sulfonylurea therapy without loss of diabetes control.
- Patients with a history of drug or alcohol dependence in the last 5 years
- Patients with pre-existing cardiovascular disease including coronary artery disease, heart attack, heart failure, abnormal heart rhythms, structural abnormalities and valve disease, peripheral vascular disease and uncontrolled high blood pressure.
- Patients with a history of high cholesterol requiring therapy.
- Patients with severe systemic disease other than diabetes which has as a recognized complication neuropathy
- Patients currently taking drugs which act on the blood vessels (for example for hypertension)
- Patients taking antidepressants, or other drugs or medications known to interfere with the uptake or metabolism of catecholamines (stress hormones)
- Patients with poor renal function or have significant liver disease
- Patients with a history of previous kidney, pancreas or cardiac transplantation.
- Patients with a history of "severe hypoglycemia" which required the assistance of a third party or ketoacidosis requiring hospital admission within the last 3 months.
- Patients with lung disease for example resulting from chronic obstructive airways disease.
- Patients with abnormal thyroid function tests.
- Patients having taken other systemic investigational drugs (especially for neuropathy) or initiating a new or experimental insulin delivery device within 3 months of starting the study.
- Patients with a history of allergic reactions to multiple drugs or biological products.
- Obese patients (BMI greater than 35).
- Patients who refuse to sign the informed consent.
Sites / Locations
- University of Michigan
- University of Toledo - Health Campus
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Myocardial blood flow regulation
Secondary Outcome Measures
biomarkers of oxidative/nitrosative stress
Full Information
NCT ID
NCT00549874
First Posted
October 24, 2007
Last Updated
November 8, 2007
Sponsor
University of Michigan
Collaborators
GlaxoSmithKline
1. Study Identification
Unique Protocol Identification Number
NCT00549874
Brief Title
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
Official Title
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
October 2007
Overall Recruitment Status
Completed
Study Start Date
February 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Michigan
Collaborators
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The overall hypothesis to be tested is that increased insulin resistance contributes to abnormal cardiac blood flow regulation in type 2 diabetic patients, which can be reversed by 6 months treatment with rosiglitazone. The planned experimental approach will be to utilize nuclear medicine techniques to evaluate whether the administration of rosiglitazone for 6 months can reverse regional deficits in myocardial blood flow and glucose utilization in type 2 diabetes in a randomized double blind controlled study. These studies will help elucidate the potential of rosiglitazone to correct deficits of myocardial blood flow complicating diabetes with the overall aim being the eventual prevention of sudden cardiac death.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
insulin resistance, type 2 diabetes, myocardial perfusion, nitrosative stress, thiazolidinediones
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
27 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Rosiglitazone
Intervention Description
oral 8 mg/once daily for 6 months
Intervention Type
Drug
Intervention Name(s)
Glyburide
Intervention Description
20 mg/ once daily for 6 months
Primary Outcome Measure Information:
Title
Myocardial blood flow regulation
Time Frame
6 months intervention
Secondary Outcome Measure Information:
Title
biomarkers of oxidative/nitrosative stress
Time Frame
6 month intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes
30-75 years of age
less than 1% fluctuation in HbA1c over 3 months
women must be on contraception
HbA1c 6-9%
willingness to sign approved consent form
Exclusion Criteria:
Nursing mothers, pregnant women (excluded by a negative pregnancy test).
Subjects requiring insulin therapy (>20 units/day) and can not be converted to sulfonylurea therapy without loss of diabetes control.
Patients with a history of drug or alcohol dependence in the last 5 years
Patients with pre-existing cardiovascular disease including coronary artery disease, heart attack, heart failure, abnormal heart rhythms, structural abnormalities and valve disease, peripheral vascular disease and uncontrolled high blood pressure.
Patients with a history of high cholesterol requiring therapy.
Patients with severe systemic disease other than diabetes which has as a recognized complication neuropathy
Patients currently taking drugs which act on the blood vessels (for example for hypertension)
Patients taking antidepressants, or other drugs or medications known to interfere with the uptake or metabolism of catecholamines (stress hormones)
Patients with poor renal function or have significant liver disease
Patients with a history of previous kidney, pancreas or cardiac transplantation.
Patients with a history of "severe hypoglycemia" which required the assistance of a third party or ketoacidosis requiring hospital admission within the last 3 months.
Patients with lung disease for example resulting from chronic obstructive airways disease.
Patients with abnormal thyroid function tests.
Patients having taken other systemic investigational drugs (especially for neuropathy) or initiating a new or experimental insulin delivery device within 3 months of starting the study.
Patients with a history of allergic reactions to multiple drugs or biological products.
Obese patients (BMI greater than 35).
Patients who refuse to sign the informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin Stevens, MD, PhD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
University of Toledo - Health Campus
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43606
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
19394661
Citation
Pop-Busui R, Oral E, Raffel D, Byun J, Bajirovic V, Vivekanandan-Giri A, Kellogg A, Pennathur S, Stevens MJ. Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. Metabolism. 2009 Jul;58(7):989-94. doi: 10.1016/j.metabol.2009.02.020.
Results Reference
derived
Learn more about this trial
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
We'll reach out to this number within 24 hrs